Bionomics’ stock skyrockets 340% after PTSD candidate passes PhIIb test

Ayisha Sharma

News Reporter

Bionomics touted the registrational potential of its post-traumatic stress disorder drug after it hit the primary endpoint in a Phase IIb trial, triggering the company’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bionomics’ stock skyrockets 340% after PTSD candidate passes PhIIb test

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Bio­nom­ics’ stock sky­rock­ets 340% af­ter PTSD can­di­date pass­es PhI­Ib test

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bionomics’ stock skyrockets 340% after PTSD candidate passes PhIIb test